CY1115098T1 - Νεο γλυκινικο αλας μετφορμινης για ελεγχο γλυκοζης αιματος - Google Patents

Νεο γλυκινικο αλας μετφορμινης για ελεγχο γλυκοζης αιματος

Info

Publication number
CY1115098T1
CY1115098T1 CY20141100150T CY141100150T CY1115098T1 CY 1115098 T1 CY1115098 T1 CY 1115098T1 CY 20141100150 T CY20141100150 T CY 20141100150T CY 141100150 T CY141100150 T CY 141100150T CY 1115098 T1 CY1115098 T1 CY 1115098T1
Authority
CY
Cyprus
Prior art keywords
metalformin
new
blood glucose
glucose control
glycin salt
Prior art date
Application number
CY20141100150T
Other languages
English (en)
Inventor
Ochoa José Manuel Francisco Lara
Original Assignee
Laboratorios Silanes, S.A. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115098(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Silanes, S.A. De C.V. filed Critical Laboratorios Silanes, S.A. De C.V.
Publication of CY1115098T1 publication Critical patent/CY1115098T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Όντος υπό σταθερή ανάδευση και κατόπιν, το προκύπτον προϊόν θερμαίνεται μέχρις ότου να παραχθεί συμπυκνωμένο διάλυμα, προστίθεται οργανικός διαλύτης, ο οποίος δεν αντιδρά με τα συστατικά που υπάρχουν και όπου η γλυκίνη είναι αδιάλυτη, για να δημιουργηθεί αδιαλυτότητα στο μέσο και να ευνοήσει κρυστάλλωση για να καθιζάνει η περίσσεια γλυκίνης και στην συνέχεια να διαχωριστεί αυτή με διήθηση. Το διήθημα δε συμπυκνώθηκε και πάλι μέχρις ότου επετεύχθη καθίζηση του γλυκινικού άλατος μετφορμίνης.
CY20141100150T 2008-06-26 2014-02-25 Νεο γλυκινικο αλας μετφορμινης για ελεγχο γλυκοζης αιματος CY1115098T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08807218.6A EP2303838B1 (en) 2008-06-26 2008-06-26 A new metformin glycinate salt for blood glucose control
PCT/IB2008/002665 WO2009144527A1 (en) 2008-06-26 2008-06-26 A new metformin glycinate salt for blood glucose control

Publications (1)

Publication Number Publication Date
CY1115098T1 true CY1115098T1 (el) 2016-12-14

Family

ID=40383805

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100150T CY1115098T1 (el) 2008-06-26 2014-02-25 Νεο γλυκινικο αλας μετφορμινης για ελεγχο γλυκοζης αιματος

Country Status (26)

Country Link
US (2) US8703183B2 (el)
EP (1) EP2303838B1 (el)
JP (1) JP5551691B2 (el)
KR (1) KR101522066B1 (el)
CN (1) CN102159539B (el)
AR (1) AR074159A1 (el)
AU (1) AU2008357111B2 (el)
BR (1) BRPI0822909B8 (el)
CA (1) CA2729035C (el)
CL (1) CL2009001484A1 (el)
CY (1) CY1115098T1 (el)
DK (1) DK2303838T3 (el)
EC (1) ECSP10010719A (el)
ES (1) ES2450148T3 (el)
HR (1) HRP20140194T1 (el)
JO (1) JO2884B1 (el)
MA (1) MA32418B1 (el)
MX (1) MX2011000135A (el)
NI (1) NI201000234A (el)
PE (1) PE20100257A1 (el)
PL (1) PL2303838T3 (el)
PT (1) PT2303838E (el)
SI (1) SI2303838T1 (el)
TN (2) TN2010000604A1 (el)
UY (1) UY31945A (el)
WO (1) WO2009144527A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303838B1 (en) 2008-06-26 2013-12-04 Laboratorios Silanes, S.A. de C.V. A new metformin glycinate salt for blood glucose control
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
CN103263405B (zh) * 2013-05-08 2015-04-22 南京医科大学 用于治疗糖尿病的药物组合物及其应用
WO2015042495A2 (en) * 2013-09-22 2015-03-26 Jiva Pharma, Inc. Metformin salts to treat type2 diabetes
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
US9999626B2 (en) 2014-06-18 2018-06-19 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
WO2016069475A1 (en) 2014-10-27 2016-05-06 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
CN105030745A (zh) * 2015-07-08 2015-11-11 南京医科大学 甘氨酸和二甲双胍的酰胺化产物在制备治疗糖尿病药物中的应用
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
BR112019006401A2 (pt) * 2016-09-30 2019-06-25 Laboratorios Silanes S A De C V glicinato de metformina, composições farmacêuticas que compreendem o mesmo e métodos de uso do mesmo
WO2018060962A2 (en) 2016-09-30 2018-04-05 Laboratorios Silanes S.A. De C.V. Metformin amino acid compounds and methods of using the same
CN113105367B (zh) * 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE568513A (el)
FR2037002A1 (en) 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
DE1967138A1 (de) 1969-07-17 1977-11-10 Christian Brunnengraeber Chem Therapeutisches mittel
AT325632B (de) 1973-06-01 1975-10-27 Hurka Wilhelm Verfahren zur herstellung von nicotinsauren salzen von derivaten des biguanids
FR2243684B1 (el) 1973-09-19 1977-01-28 Semb
CH602612A5 (el) 1974-10-11 1978-07-31 Hoffmann La Roche
FR2320735A1 (fr) 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
JPS57179494A (en) 1981-04-30 1982-11-05 Mitsubishi Plastics Ind Method of closing through hole of pipe, circumferential wall thereof has through hole in pipe axial direction
FR2585572B3 (fr) 1985-07-31 1987-12-31 Hugelin Andre Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
DE793646T1 (de) * 1994-11-23 1999-12-30 Upjohn Co Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus
JP4278863B2 (ja) 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
WO2003068209A1 (en) * 2002-02-14 2003-08-21 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7181457B2 (en) * 2003-05-28 2007-02-20 Pervasive Software, Inc. System and method for utilizing compression in database caches to facilitate access to database information
EP1677757A2 (en) 2003-10-31 2006-07-12 Alza Corporation Compositions and dosage forms for enhanced absorption
WO2005065675A1 (en) * 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Method of treatment
WO2006086856A1 (en) * 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
JP2009506978A (ja) * 2005-04-27 2009-02-19 メッサデク ジャアル インスリン類の併用
CN101522658A (zh) * 2006-06-16 2009-09-02 因迪基恩药物公司 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐
NZ556735A (en) * 2007-07-24 2009-03-31 Vector Ltd Securing devices and equipotential bonding system
EP2303838B1 (en) 2008-06-26 2013-12-04 Laboratorios Silanes, S.A. de C.V. A new metformin glycinate salt for blood glucose control

Also Published As

Publication number Publication date
SI2303838T1 (sl) 2014-07-31
AU2008357111B2 (en) 2013-05-09
CL2009001484A1 (es) 2009-12-04
AR074159A1 (es) 2010-12-29
ES2450148T3 (es) 2014-03-24
DK2303838T3 (en) 2014-03-03
HRP20140194T1 (hr) 2014-06-20
BRPI0822909B1 (pt) 2019-11-12
BRPI0822909B8 (pt) 2021-05-25
BRPI0822909A2 (pt) 2015-06-30
UY31945A (es) 2010-01-05
TN2010000607A1 (en) 2012-05-24
TN2010000604A1 (en) 2012-05-24
US8703183B2 (en) 2014-04-22
JP2011525900A (ja) 2011-09-29
JP5551691B2 (ja) 2014-07-16
CA2729035C (en) 2015-10-20
PE20100257A1 (es) 2010-04-10
KR101522066B1 (ko) 2015-05-20
EP2303838A1 (en) 2011-04-06
AU2008357111A1 (en) 2009-12-03
USRE46496E1 (en) 2017-08-01
KR20110042165A (ko) 2011-04-25
MX2011000135A (es) 2011-02-25
PL2303838T3 (pl) 2014-07-31
WO2009144527A1 (en) 2009-12-03
CA2729035A1 (en) 2009-12-03
EP2303838B1 (en) 2013-12-04
US20110171142A1 (en) 2011-07-14
PT2303838E (pt) 2014-03-10
NI201000234A (es) 2012-03-19
CN102159539B (zh) 2014-04-16
MA32418B1 (fr) 2011-06-01
ECSP10010719A (es) 2011-01-31
CN102159539A (zh) 2011-08-17
JO2884B1 (en) 2015-03-15

Similar Documents

Publication Publication Date Title
CY1115098T1 (el) Νεο γλυκινικο αλας μετφορμινης για ελεγχο γλυκοζης αιματος
CY1110608T1 (el) Νεα μεθοδος για παρασκευη κρυσταλλικης ερβουμινης της περινδοπριλης
CY1108762T1 (el) Υποκατεστημενα αρυλικα και ετεροαρυλικα παραγωγα ως ρυθμιστες του μεταβολισμου και η προφυλαξη και αντιμετωπιση διαταραχων που σχετιζονται με αυτον
CY1106837T1 (el) Μεθοδος παραγωγης κρυσταλλων νατεγλινιδιου
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
BR112018005284A2 (pt) ácido nucleico interligado guna, método para produzir o mesmo, e composto intermediário
NO20054100D0 (no) Fremgangsmate for fremstilling av syreaddisjonssalter
BRPI0512927A (pt) método para produzir e purificar gelatina
BR112019009078A2 (pt) processo para a purificação de pirazolpiridazinas, sal e composição agrícola
EA201070228A1 (ru) Тразодон и гидрохлорид тразодона в очищенной форме
CN109721502A (zh) 一种邻氯苯甘氨酸的制备方法
Zhang et al. Bipyridinium radical cation dimerization-driven polymeric pleated foldamers and a homoduplex that undergo ion-tuned interconversion
PE20140200A1 (es) Metodo para producir y usar un copolimero de carboximetilcelulosa sodica y gosipol
DE502007002666D1 (de) Neue phosphatierte Organosiloxanylderivate und deren Verwendung zur Behandlung von Leder
ATE420839T1 (de) Halogenidarme polymerlösung mit kationischen aminogruppen, ihre herstellung und ihre verwendung
MY175861A (en) Method for purifying 1,4-diaminobutane, 1, 4-diaminobutane purified by said method, and polyamide prepared therefrom
ATE513835T1 (de) Verfahren zur herstellung von cefotetan
CN104098616A (zh) 一种蔗糖铁的制备方法
CN103981248A (zh) 一种拆分外消旋亮氨酸的方法
RU2013132528A (ru) Способ получения лактата
ATE512127T1 (de) Verfahren zur herstellung optisch aktiver alpha- alkylcarbonylverbindungen
RU2008101238A (ru) Способ получения устойчивых солей арилдиазония
UA60983U (en) Process for processing of phosphogypsum
CN105481729B (zh) 一种dl-高磺基丙氨酸的制备方法
RU2009117379A (ru) Способ получения микроэлементного лекарственного средства на основе железодекстранового или железодекстринового комплекса